



PRESS RELEASE

Bulletin from the Extraordinary General Meeting of Lipidor AB (publ)

STOCKHOLM, Sweden, 8 June 2021: The following resolutions were passed at the extraordinary general meeting (the "EGM") of Lipidor (publ) (the "Company") on 8 June 2021. Due to the covid-19 pandemic, the Company's extraordinary general meeting was carried out through advance voting (postal voting) only.

Incentive programme in the subsidiary Emollivet AB

The EGM resolved, in accordance with the Board of Directors' proposal, to approve of the subsidiary Emollivet AB's resolution to adopt an incentive programme to the management in Emollivet AB consisting of warrants. In short, the incentive programme includes an issue of not more than 50 warrants in Emollivet AB and was conditional upon the approval of the general meeting in the Company. Each warrant entitles the holder to subscribe for shares in Emollivet AB during the period 1 January 2026 up to and including 30 June 2026.

Furthermore, the EGM resolved, in accordance with the Board of Directors' proposal, to approve of Emollivet AB's resolution to adopt an incentive programme to members of the Board of Directors of Emollivet AB consisting of warrants. In short, the incentive programme includes an issue of not more than 50 warrants and was also conditional upon the approval of the general meeting in the Company. Each warrant entitles the holder to subscribe for shares in Emollivet AB during the period 1 January 2026 up to and including 30 June 2026.

Information

The information was provided for publication through the office of Lipidor's CEO on 8 June 2021 at 12.35pm (CEST).

For more information, please contact:

Ola Holmlund, CEO
Telephone: +46 (0)72 50 70 369
Email: ola.holmlund@lipidor.se

Certified Adviser

Erik Penser Bank AB
Telephone: +46 (0)8 463 80 00
E-mail: certifiedadviser@penser.se

About Lipidor AB

Lipidor AB (www.lipidor.se) is a Swedish, Stockholm-based research and development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The Company develops topical medical products for the treatment of diseases such as psoriasis, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances.